Diabetic gastroparesis and its impact on glycemia

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 4, 2010, Pages 745-762

  Chang, Jessica ^a,b   Rayner, Christopher K ^a,b   Jones, Karen L ^a,b   Horowitz, Michael ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b NHMRC Centre of Clinical Research Excellence in Nutritional Physiology   (Australia)

Author keywords

Diabetes; Gastric emptying; Incretin

Indexed keywords

ANTIEMETIC AGENT; BOTULINUM TOXIN; CHOLECYSTOKININ; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOMPERIDONE; ERYTHROMYCIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEME OXYGENASE 1; HEMIN; INSULIN; METOCLOPRAMIDE; NEURONAL NITRIC OXIDE SYNTHASE; PEPTIDE YY; PRAMLINTIDE; PROCHLORPERAZINE; PROKINETIC AGENT;

BREATH ANALYSIS; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ECHOGRAPHY; ELECTROSTIMULATION THERAPY; GASTROINTESTINAL SYMPTOM; GASTROSTOMY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MANOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TRANSPLANTATION; PARTIAL GASTRECTOMY; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH EMPTYING; STOMACH PARESIS; STOMACH SCINTISCANNING; TELEMETRY; TOTAL STOMACH RESECTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC NEUROPATHIES; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; HYPOGLYCEMIA; HYPOTENSION; POSTPRANDIAL PERIOD;

EID: 78649345278     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.08.007     Document Type: Review

References (104)

1. Horowitz M., O'Donovan D., Jones K.L., et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002, 19(3):177-194.
2. Horowitz M., Maddox A.F., Wishart J.M., et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991, 18(4):229-234.
3. Horowitz M., Wishart J.M., Jones K.L., et al. Gastric emptying in diabetes: an overview. Diabet Med 1996, 13(9 Suppl 5):S16-S22.
4. Horowitz M., Su Y.C., Rayner C.K., et al. Gastroparesis: prevalence, clinical significance and treatment. Can J Gastroenterol 2001, 15(12):805-813.
5. Jones K.L., Horowitz M., Wishart M.J., et al. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med 1995, 36(12):2220-2228.
6. Kong M.F., Horowitz M., Jones K.L., et al. Natural history of diabetic gastroparesis. Diabetes Care 1999, 22(3):503-507.
7. Wang Y.R., Fisher R.S., Parkman H.P. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol 2008, 103(2):313-322.
8. Ma J., Rayner C.K., Jones K.L., et al. Diabetic gastroparesis: diagnosis and management. Drugs 2009, 69(8):971-986.
9. Khoo J., Rayner C.K., Jones K.L., et al. Pathophysiology and management of gastroparesis. Expert Rev Gastroenterol Hepatol 2009, 3(2):167-181.
10. Jones K.L., Horowitz M., Carney B.I., et al. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med 1996, 37(10):1643-1648.
11. Horowitz M., Edelbroek M.A., Wishart J.M., et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993, 36(9):857-862.
12. Jones K.L., Tonkin A., Horowitz M., et al. Rate of gastric emptying is a determinant of postprandial hypotension in non-insulin-dependent diabetes mellitus. Clin Sci (Lond) 1998, 94(1):65-70.
13. Rayner C.K., Horowitz M. New management approaches for gastroparesis. Nat Clin Pract Gastroenterol Hepatol 2005, 2(10):454-462. [quiz: 93].
14. Jones M.P., Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003, 98(10):2122-2129.
15. Samsom M., Vermeijden J.R., Smout A.J., et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 2003, 26(11):3116-3122.
16. Jones K.L., Russo A., Berry M.K., et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med 2002, 113(6):449-455.
17. Bharucha A.E., Camilleri M., Forstrom L.A., et al. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) 2009, 70(3):415-420.
18. Brener W., Hendrix T.R., McHugh P.R. Regulation of the gastric emptying of glucose. Gastroenterology 1983, 85(1):76-82.
19. Lin H.C., Doty J.E., Reedy T.J., et al. Inhibition of gastric emptying by glucose depends on length of intestine exposed to nutrient. Am J Physiol 1989, 256(2 Pt 1):G404-G411.
20. Fried M., Erlacher U., Schwizer W., et al. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991, 101(2):503-511.
21. Deane A.M., Nguyen N.Q., Stevens J.E., et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010, 95(1):215-221.
22. Horowitz M., Jones K.L., Akkermans L.M., et al. Gastric function. Gastrointestinal function in diabetes mellitus 2004, 117-176. John Wiley & Sons Ltd, Chichester (United Kingdom). M.S.M. Horowitz (Ed.).
23. Pasricha P.J., Pehlivanov N.D., Gomez G., et al. Changes in the gastric enteric nervous system and muscle: a case report on two patients with diabetic gastroparesis. BMC Gastroenterol 2008, 8:21.
24. He C.L., Soffer E.E., Ferris C.D., et al. Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001, 121(2):427-434.
25. Samsom M., Akkermans L.M., Jebbink R.J., et al. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997, 40(5):641-646.
26. Forster J., Damjanov I., Lin Z., et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg 2005, 9(1):102-108.
27. Watkins C.C., Sawa A., Jaffrey S., et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000, 106(3):373-384.
28. Choi K.M., Gibbons S.J., Nguyen T.V., et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 2008, 135(6):2055-2064. 64 e1-2.
29. Kashyap P.C., Choi K.M., Dutta N., et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am J Physiol Gastrointest Liver Physiol 2010, 298(6):G1013-G1019.
30. Choi K.M., Kashyap P.C., Dutta N., et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology 2010, 138(7):2399-2409.
31. Bharucha A.E., Kulkarni A., Choi K.M., et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin Pharmacol Ther 2010, 87(2):187-190.
32. Rayner C.K., Samsom M., Jones K.L., et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24(2):371-381.
33. Fraser R.J., Horowitz M., Maddox A.F., et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990, 33(11):675-680.
34. Schvarcz E., Palmer M., Aman J., et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997, 113(1):60-66.
35. Jebbink R.J., Samsom M., Bruijs P.P., et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994, 107(5):1390-1397.
36. Hebbard G.S., Samsom M., Sun W.M., et al. Hyperglycemia affects proximal gastric motor and sensory function during small intestinal triglyceride infusion. Am J Physiol 1996, 271(5 Pt 1):G814-G819.
37. Rayner C.K., Su Y.C., Doran S.M., et al. The stimulation of antral motility by erythromycin is attenuated by hyperglycemia. Am J Gastroenterol 2000, 95(9):2233-2241.
38. Jones K.L., Berry M., Kong M.F., et al. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999, 22(2):339-344.
39. Jones K.L., Kong M.F., Berry M.K., et al. The effect of erythromycin on gastric emptying is modified by physiological changes in the blood glucose concentration. Am J Gastroenterol 1999, 94(8):2074-2079.
40. Russo A., Stevens J.E., Chen R., et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005, 90(8):4489-4495.
41. Abell T.L., Camilleri M., Donohoe K., et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol 2008, 36(1):44-54.
42. Wright R.A., Clemente R., Wathen R. Diabetic gastroparesis: an abnormality of gastric emptying of solids. Am J Med Sci 1985, 289(6):240-242.
43. Viramontes B.E., Kim D.Y., Camilleri M., et al. Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. Neurogastroenterol Motil 2001, 13(6):567-574.
44. Chew C.G., Bartholomeusz F.D., Bellon M., et al. Simultaneous 13C/14C dual isotope breath test measurement of gastric emptying of solid and liquid in normal subjects and patients: comparison with scintigraphy. Nucl Med Rev Cent East Eur 2003, 6(1):29-33.
45. 13C]-acetate breath test with Wagner-Nelson analysis in humans. Clin Exp Pharmacol Physiol 2006, 33(12):1239-1243.
46. Hveem K., Jones K.L., Chatterton B.E., et al. Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996, 38(6):816-821.
47. Gilja O.H., Hausken T., degaard S., et al. Gastric emptying measured by ultrasonography. World J Gastroenterol 1999, 5(2):93-94.
48. Gentilcore D., Hausken T., Horowitz M., et al. Measurements of gastric emptying of low- and high-nutrient liquids using 3D ultrasonography and scintigraphy in healthy subjects. Neurogastroenterol Motil 2006, 18(12):1062-1068.
49. Kunz P., Feinle C., Schwizer W., et al. Assessment of gastric motor function during the emptying of solid and liquid meals in humans by MRI. J Magn Reson Imaging 1999, 9(1):75-80.
50. Schwizer W., Fraser R., Borovicka J., et al. Measurement of gastric emptying and gastric motility by magnetic resonance imaging (MRI). Dig Dis Sci 1994, 39(Suppl 12):101S-103S.
51. Kuo B., McCallum R.W., Koch K.L., et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 2008, 27(2):186-196.
52. Verhagen M.A., Van Schelven L.J., Samsom M., et al. Pitfalls in the analysis of electrogastrographic recordings. Gastroenterology 1999, 117(2):453-460.
53. Parkman H.P., Hasler W.L., Barnett J.L., et al. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil 2003, 15(2):89-102.
54. Willems M., Quartero A.O., Numans M.E. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001, 46(10):2256-2262.
55. Olausson E.A., Alpsten M., Larsson A., et al. Small particle size of a solid meal increases gastric emptying and late postprandial glycaemic response in diabetic subjects with gastroparesis. Diabetes Res Clin Pract 2008, 80(2):231-237.
56. Lacy B.E., Zayat E.N., Crowell M.D., et al. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002, 97(6):1548-1552.
57. Miller L.S., Szych G.A., Kantor S.B., et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002, 97(7):1653-1660.
58. Arts J., Holvoet L., Caenepeel P., et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007, 26(9):1251-1258.
59. Friedenberg F.K., Palit A., Parkman H.P., et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008, 103(2):416-423.
60. McCallum R.W., Chen J.D., Lin Z., et al. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998, 114(3):456-461.
61. Abell T., McCallum R., Hocking M., et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003, 125(2):421-428.
62. O'Grady G., Egbuji J.U., Du P., et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg 2009, 33(8):1693-1701.
63. McCallum R., Brody F., Parkman H.P., et al. Enterra gastric electrical stimulation for diabetic gastroparesis:results from a multicenter randomized study. Gastroenterology 2009, 136:A61-A62.
64. Ejskjaer N.T., Bradley J.L., Buxton-Thomas M.S., et al. Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabet Med 1999, 16(6):488-495.
65. Watkins P.J., Buxton-Thomas M.S., Howard E.R. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabet Med 2003, 20(1):58-63.
66. Takanashi H., Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept 2009, 155(1-3):18-23.
67. Ejskjaer N., Vestergaard E.T., Hellstrom P.M., et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009, 29(11):1179-1187.
68. Murray C.D., Martin N.M., Patterson M., et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005, 54(12):1693-1698.
69. Parkman H.P., Camilleri M., Farrugia G., et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil 2010, 22(2):113-133.
70. Gentilcore D., Jones K.L., O'Donovan D.G., et al. Postprandial hypotension - novel insights into pathophysiology and therapeutic implications. Curr Vasc Pharmacol 2006, 4(2):161-171.
71. Gentilcore D., Bryant B., Wishart J.M., et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med 2005, 118(11):1289.
72. Ma J., Rayner C.K., Jones K.L., et al. Insulin secretion in healthy subjects and patients with type 2 diabetes-role of the gastrointestinal tract. Best Pract Res Clin Endocrinol Metab 2009, 23(4):413-424.
73. Rayner C.K., Horowitz M. Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited?. J Clin Invest 2006, 116(2):299-302.
74. Ceriello A., Hanefeld M., Leiter L., et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004, 164(19):2090-2095.
75. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26(3):881-885.
76. Horowitz M., Nauck M.A. To be or not to be-an incretin or enterogastrone?. Gut 2006, 55(2):148-150.
77. Meier J.J. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2009, 23(4):433-441.
78. Meier J.J., Nauck M.A. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes 2010, 59(5):1117-1125.
79. Nauck M.A., Heimesaat M.M., Orskov C., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91(1):301-307.
80. Meier J.J., Hucking K., Holst J.J., et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001, 50(11):2497-2504.
81. Meier J.J., Gallwitz B., Kask B., et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004, 53(Suppl 3):S220-S224.
82. Vilsboll T., Krarup T., Madsbad S., et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002, 45(8):1111-1119.
83. Horowitz M., Harding P.E., Maddox A.F., et al. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J Gastroenterol Hepatol 1986, 1:97-113.
84. Wolever T.M., Bolognesi C. Source and amount of carbohydrate affect postprandial glucose and insulin in normal subjects. J Nutr 1996, 126(11):2798-2806.
85. Pearce K.L., Noakes M., Keogh J., et al. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. Am J Clin Nutr 2008, 87(3):638-644.
86. Ishii M., Nakamura T., Kasai F., et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994, 17(8):901-903.
87. Pilichiewicz A.N., Chaikomin R., Brennan I.M., et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007, 293(3):E743-E753.
88. Rayner C.K., Chapman M.J., Pilichiewicz A., et al. Effects of variations in duodenal glucose load on glycaemia, insulin and GLP-1 in type 2 diabetes (Abstract). Diabetologia 2009, 52(Suppl 1):S105.
89. O'Donovan D.G., Doran S., Feinle-Bisset C., et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 2004, 89(7):3431-3435.
90. Chaikomin R., Doran S., Jones K.L., et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005, 289(3):E504-E507.
91. Lysy J., Israeli E., Strauss-Liviatan N., et al. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil 2006, 18(6):433-440.
92. Horowitz M., Jones K.L., Rayner C.K., et al. 'Gastric' hypoglycaemia-an important concept in diabetes management. Neurogastroenterol Motil 2006, 18(6):405-407.
93. Chandalia M., Garg A., Lutjohann D., et al. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000, 342(19):1392-1398.
94. Russo A., Stevens J.E., Wilson T., et al. Guar attenuates fall in postprandial blood pressure and slows gastric emptying of oral glucose in type 2 diabetes. Dig Dis Sci 2003, 48(7):1221-1229.
95. Gentilcore D., Chaikomin R., Jones K.L., et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 2006, 91(6):2062-2067.
96. Ma J., Stevens J.E., Cukier K., et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009, 32(9):1600-1602.
97. Vella A., Lee J.S., Camilleri M., et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002, 14(2):123-131.
98. Thompson R.G., Pearson L., Schoenfeld S.L., et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 1998, 21(6):987-993.
99. Aronne L., Fujioka K., Aroda V., et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007, 92(8):2977-2983.
100. Little T.J., Pilichiewicz A.N., Russo A., et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006, 91(5):1916-1923.
101. Linnebjerg H., Park S., Kothare P.A., et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008, 151(1-3):123-129.
102. Gutzwiller J.P., Drewe J., Goke B., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276(5 Pt 2):R1541-R1544.
103. Delgado-Aros S., Vella A., Camilleri M., et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil 2003, 15(4):435-443.
104. Vella A., Bock G., Giesler P.D., et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf) 2008, 69(5):737-744.